Laurus Labs Limited vs Plethico Pharmaceuticals Ltd

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Plethico Pharmaceuticals Ltd (PLETHICO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads LAURUSLABS vs PLETHICO on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability40
  • Growth11
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

PLETHICO takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.08
P/E ratio
0.00
19.74
P/B ratio
0.00
0.10%
Dividend yield
0.00%
₹16.47
EPS
₹32.49

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
7.43%
17.58%
Return on capital
10.00%
26.09%
EBITDA margin
14.00%
13.07%
Net margin
5.39%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y)
10.45%
3.91%
Profit CAGR (3Y)
-23.09%

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹0 Cr
₹6,813 Cr
Revenue
₹2,060 Cr
₹890 Cr
Net profit
₹111 Cr
0.45
Debt / equity
0.00
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 20.99 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Plethico Pharmaceuticals Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.02 times its book value"]
  • − ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has low interest coverage ratio.", "Company has a low return on equity of 9.07% over last 3 years.", "Contingent liabilities of Rs.1,518 Cr.", "Company has high debtors of 198 days.", "Company's cost of borrowing seems high"]
Laurus Labs Limited full analysis Plethico Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.